Lilly Asia, Qiming, HongShan et al Double Down on Cell Therapy Tech
22 Oct 2024
US$ 19.00
Lilly Asia Ventures, Qiming Venture Partners, HongShan and FreesFund, all existing investors of XellSmart ......
Tag
Biotech
Related Publications
360 ONE Asset Management (360 ONE) is to conclude its investment in Bharti Life Insurance Co Ltd (Bharti Life) as the...
Vivo Capital has led the over Rmb1 bn (US$150 m) series D funding round of Shanghai Full-Life Technologies Co Ltd...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.